FDA Clears DiaSorin HSV Assay for Extended Swab Sample Claims

Jun 21, 2018

|

The article has been updated to correct the types of new samples covered by the expanded FDA clearance.

NEW YORK (GenomeWeb) – DiaSorin Molecular said today it has received a US Food and Drug Administration clearance that extends the sample type claims for its Simplexa HSV 1 & 2 Direct assay, expanding the type of samples that can be tested to all cutaneous and mucocutaneous swab samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Featured White Papers

FFPE controls for use with Ion AmpliSeq and Oncomine ALK, RET, and ROS1 fusion assays

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Discovering Neuronal Cell Types

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Main menu